Articulatory Adaptation Following Oral Cancer Treatment
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · May 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how surgery for oral cancer affects speech, particularly how well patients can coordinate their speech movements after treatment. Researchers want to understand if differences in how patients use sound (hearing) or touch (feeling) can help predict how well they adapt their speech after surgery. Participants will be asked to perform various speech tasks while special sensors track their mouth movements.
To join the study, you need to be at least 18 years old, speak Dutch as your first language, and have been diagnosed with a specific type of oral cancer (a tumor in the mouth) that hasn't been treated before. The study is currently looking for participants, and it’s open to both men and women. If you decide to participate, you will undergo several speech tasks, and your movements will be closely monitored to help researchers learn more about how speech changes after cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosed with T1 or T2 tumor in the oral cavity
- • 2. At least 18 years old and able to provide informed consent
- • 3. Native speaker of Dutch
- • 4. Has nog been treated for oral cancer before
- Exclusion Criteria:
- • 1a. Recurrence of disease (for patients)
- • 1b. Treated for oral cancer (for healthy controls) 2. Speech problems (e.g., stuttering) 3. Problems with sight or hearing that impede reading or understanding instructions. When glasses or a hearing aid resolve these problems, then participants are not excluded.
- • 4. Neurological or psychological disorders (e.g., stroke) 5. Non-removable metal in, on or around the head (piercings, braces, pacemaker, electrodes) 6. Self-reported signs of depression
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Groningen, , Netherlands
Patients applied
Trial Officials
Max Witjes, PhD
Principal Investigator
University of Groningen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported